Key result
Cardiac catheterization in pediatric cardiomyopathy carries a ~3% major complication rate, higher in infants and HCM.
Why the study?
Data on procedure-related major adverse events during cardiac catheterization in children with cardiomyopathy are lacking.
What is the rate and what are the predictors of major adverse events during cardiac catheterization in pediatric patients with cardiomyopathy?
Observational (n=4,932)
Yes
What is the rate and what are the predictors of major adverse events during cardiac catheterization in pediatric patients with cardiomyopathy?
Cardiac catheterization in pediatric cardiomyopathy has a low overall major adverse event rate of 3.17%, though risk is elevated in infants, those with hypertrophic cardiomyopathy, and patients requiring inotropic support.
No takes yet. Share an insight, caveat, or question.
Calls for heightened vigilance in infants and HCM during catheterization; leaves open prospective trials to validate and mitigate risks.
Background Despite the role of cardiac catheterization for hemodynamic assessment and endomyocardial biopsy in children with cardiomyopathy, data on procedure‐related major adverse events (MAE) in this population are lacking. We aim to describe the rate of MAE in children with cardiomyopathy undergoing cardiac catheterization. Our secondary objective is to compare the rate of MAE among patient subsets within this population. Methods We included patients with cardiomyopathy from the National Cardiovascular Data Registry IMPACT (Improving Pediatric and Adult Congenital Treatment) who were 18 years old or younger and underwent cardiac catheterization between April 2016 and December 2024. Data collected included demographic, preprocedural, procedural, and outcome‐related variables. We performed univariate and multivariate analyses to identify variables independently associated with MAE. Results A total of 4932 procedures were evaluated, with a median age of 10 years. Dilated cardiomyopathy was the most prevalent cardiomyopathy in 53.4%. The rate of MAE was 3.17%. The most common MAE was arrhythmia, representing 42.3% of all MAE. The multivariate analysis also revealed that age <1 year, hypertrophic cardiomyopathy compared with dilated cardiomyopathy, preprocedural inotropic support, left femoral venous access, and systemic heparinization were associated with an increased rate of MAE. In contrast, procedures performed electively were associated with a lower risk of MAE. Conclusions Cardiac catheterization in pediatric patients with cardiomyopathy was associated with low incidence of MAE as compared with the general pediatric population. Factors associated with an increased rate of MAE include age <1 year, hypertrophic cardiomyopathy, inotropic support, left femoral venous access, and systemic heparinization.
Aldawsari et al. (2026) conducted an observational in Pediatric cardiomyopathy (n=4,932). Cardiac catheterization was evaluated on Procedure-related major adverse events (MAE). Cardiac catheterization in pediatric patients with cardiomyopathy had a 3.17% rate of major adverse events, with increased risk in those aged <1 year or with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: